Back to Journals » OncoTargets and Therapy » Volume 2

Gemcitabine for the treatment of advanced nonsmall cell lung cancer

Authors Toschi L, Cappuzzo F

Published 3 August 2009 Volume 2009:2 Pages 209—217

DOI https://doi.org/10.2147/OTT.S4645

Review by Single anonymous peer review

Peer reviewer comments 2


Luca Toschi1, Federico Cappuzzo2

1Dana-Farber Cancer Institute, Medical Oncology, Boston, MA, USA; 2Istituto Clinico Humanitas IRCCS, Department of Onco-Hematology, Rozzano, Italy

Abstract: Gemcitabine is a pyrimidine nucleoside antimetabolite agent which is active in several human malignancies, including nonsmall cell lung cancer (NSCLC). Because of its acceptable toxicity profile, with myelosuppression being the most common adverse event, gemcitabine can be safely combined with a number of cytotoxic agents, including platinum derivatives and new-generation anticancer compounds. In fact, the combination of gemcitabine and cisplatin is a first-line treatment for patients with advanced NSCLC, pharmacoeconomic data indicating that it represents the most cost-effective regimen among platinum-based combinations with thirdgeneration cytotoxic drugs. The drug has been investigated in the context of nonplatinum-based regimens in a number of prospective clinical trials, and might provide a suitable alternative for patients with contraindications to platinum. Recently, gemcitabine-based doublets have been successfully tested in association with novel targeted agents with encouraging results, providing further evidence for the role of the drug in the treatment of NSCLC. In the last few years several attempts have been pursued in order to identify molecular predictors of gemcitabine activity, and recent data support the feasibility of genomic-based approaches to customize treatment with the ultimate goal of improving patient outcome.

Keywords: gemcitabine, chemotherapy, pharmacoeconomics, nonsmall cell lung cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]